autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome
MONDO:0018636
Outbreak surveillance
Global reported eventsExplore recent public health notices potentially related to autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome. Results are keyword matches, not yet verified disease-to-outbreak relationships.
View autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome on the outbreak map →TRIANGLE disease
TRIANGLE disease is a rare genetic disorder of the immune system. TRIANGLE stands for "TPPII-related immunodeficiency, autoimmunity, and neurodevelopmental delay with impaired glycolysis and lysosomal expansion" where TPP2 is the causative gene. This disease manifests as recurrent infection, autoimmunity, and neurodevelopmental delay. TRIANGLE disease was first described in a collaborative study by Dr. Helen C. Su from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and Dr. Sophie Hambleton from the University of Newcastle and their collaborators in 2014. The disease was also described by the group of Ehl et al.
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Drugs being studied
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.